16.46
Pharming Group Nv Adr Borsa (PHAR) Ultime notizie
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group to report first quarter 2026 financial results and provide business update on May 7 - GlobeNewswire Inc.
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Pharming Group N.V. Investigated by the Portnoy Law Firm - GlobeNewswire
Pharming (NASDAQ: PHAR) updates 20-F with corrected CEO/CFO certifications - Stock Titan
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 33.9% in March - MarketBeat
Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright - defenseworld.net
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
HC Wainwright Estimates Pharming Group Q3 Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest - MarketBeat
HC Wainwright Predicts Pharming Group Q1 Earnings - MarketBeat
A2QLQY Stock Price and Chart — LS:A2QLQY - TradingView
Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance - Investing.com India
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Finviz
Pharming Group Prepares to Announce Q4 Results: What Can Investors Expect? - Bitget
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Drop in Short Interest - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V.PHAR - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - GlobeNewswire Inc.
FY2025 EPS Estimates for Pharming Group Increased by Analyst - Defense World
Pharming shares surge as 2026 guidance tops analyst expectations - Investing.com
Pharming Group stock tumbles after FDA issues Complete Response Letter - Investing.com
Pharming Group (NASDAQ:PHAR) Sets New 1-Year HighTime to Buy? - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group stock hits 52-week high at 18.6 USD - Investing.com
Pharming Group (NASDAQ:PHAR) Cut to Hold at Zacks Research - Defense World
Pharming Group (NASDAQ:PHAR) Shares Gap Down After Analyst Downgrade - Defense World
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's What Happened - MarketBeat
Pharming Group (NASDAQ:PHAR) Trading Up 4.4% – Here’s Why - Defense World
Pharming Group (NASDAQ:PHAR) Hits New 1-Year High – Still a Buy? - Defense World
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Rises By 102.0% - MarketBeat
Pharming Group stock hits 52-week high at 18.19 USD - Investing.com
Best Momentum Stocks to Buy for Dec. 22 - Yahoo Finance Singapore
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Pharming Group (NASDAQ:PHAR) Hits New 12-Month HighShould You Buy? - MarketBeat
Operating expenses (excl. COGS) of Pharming Group NV Sponsored ADR – LSX:A2QLQY - TradingView
Pharming Group (NASDAQ:PHAR) Stock Price Up 11%Time to Buy? - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):